Could a new drug ease core autism symptoms in adults? phase 2 trial launches
Symptom relief
Recruiting now
This study tests whether a drug called TB006 can improve core autism symptoms in adults aged 18-35 with moderate or greater autism severity. About 45 participants will receive either TB006 or a placebo for 14 weeks, with all participants having a chance to receive TB006 later. Th…
Phase: PHASE2 • Sponsor: Rossignol Medical Center • Aim: Symptom relief
Last updated May 16, 2026 21:43 UTC